WO2008020091A8 - Formulación farmacéutica para el tratamiento de afecciones - Google Patents

Formulación farmacéutica para el tratamiento de afecciones Download PDF

Info

Publication number
WO2008020091A8
WO2008020091A8 PCT/ES2006/000483 ES2006000483W WO2008020091A8 WO 2008020091 A8 WO2008020091 A8 WO 2008020091A8 ES 2006000483 W ES2006000483 W ES 2006000483W WO 2008020091 A8 WO2008020091 A8 WO 2008020091A8
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutical formulation
complaints
relates
mainly
Prior art date
Application number
PCT/ES2006/000483
Other languages
English (en)
French (fr)
Other versions
WO2008020091A1 (es
Inventor
Barranco Enrique Rossell
Original Assignee
Klever Mode S L
Barranco Enrique Rossell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klever Mode S L, Barranco Enrique Rossell filed Critical Klever Mode S L
Priority to CN2006800561118A priority Critical patent/CN101522198B/zh
Priority to MX2009001631A priority patent/MX2009001631A/es
Priority to AU2006347403A priority patent/AU2006347403A1/en
Priority to BRPI0621966-7A priority patent/BRPI0621966A2/pt
Priority to CA002661064A priority patent/CA2661064A1/en
Publication of WO2008020091A1 publication Critical patent/WO2008020091A1/es
Priority to IL197035A priority patent/IL197035A0/en
Publication of WO2008020091A8 publication Critical patent/WO2008020091A8/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica caracterizada porque comprende principalmente clobetasolpropionato, minoxidil, y 11 alfa hidroxiprogesterona como principios activos además de otros excipientes, vitaminas y/o minerales, y a su uso en el tratamiento de afecciones en la piel, principalmente en el tratamiento sintomático de psoriasis.
PCT/ES2006/000483 2006-08-17 2006-08-22 Formulación farmacéutica para el tratamiento de afecciones WO2008020091A1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2006800561118A CN101522198B (zh) 2006-08-17 2006-08-22 用于治疗牛皮癣的药用制剂
MX2009001631A MX2009001631A (es) 2006-08-17 2006-08-22 Formulacion farmaceutica para el tratamiento de afecciones en la piel.
AU2006347403A AU2006347403A1 (en) 2006-08-17 2006-08-22 Pharmaceutical formula for treating skin disease
BRPI0621966-7A BRPI0621966A2 (pt) 2006-08-17 2006-08-22 formulaÇaÕ farmacÊutica para uso em tratamento de doenÇas de pele
CA002661064A CA2661064A1 (en) 2006-08-17 2006-08-22 Pharmaceutical formula for treating skin disease
IL197035A IL197035A0 (en) 2006-08-17 2009-02-12 Pharmaceutical formula for treating skin disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380229.2 2006-08-17
EP06380229A EP1891960B1 (en) 2006-08-17 2006-08-17 Pharmaceutical formula for treating skin disease

Publications (2)

Publication Number Publication Date
WO2008020091A1 WO2008020091A1 (es) 2008-02-21
WO2008020091A8 true WO2008020091A8 (es) 2009-04-02

Family

ID=37499927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/000483 WO2008020091A1 (es) 2006-08-17 2006-08-22 Formulación farmacéutica para el tratamiento de afecciones

Country Status (15)

Country Link
US (1) US7671044B2 (es)
EP (1) EP1891960B1 (es)
CN (1) CN101522198B (es)
AT (1) ATE444071T1 (es)
AU (1) AU2006347403A1 (es)
BR (1) BRPI0621966A2 (es)
CA (1) CA2661064A1 (es)
DE (1) DE602006009511D1 (es)
DK (1) DK1891960T3 (es)
ES (1) ES2334381T3 (es)
IL (1) IL197035A0 (es)
MX (1) MX2009001631A (es)
PT (1) PT1891960E (es)
RU (1) RU2432952C2 (es)
WO (1) WO2008020091A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2893979B2 (es) * 2020-08-01 2023-02-21 Mc Zosimo S L Procedimiento para la obtención de una formulación para el tratamiento de dermatitis inflamatorias y producto obtenido

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903344B1 (en) * 1997-08-21 2011-01-26 Shiseido Co., Ltd. Quinazolin-4-one derivatives, their preparation and their use as hair growth promoters or in external compositions for skin
AU3212099A (en) * 1998-03-31 1999-10-18 Johnson & Johnson Consumer Companies, Inc. Method for increasing the permeability of horny human tissue
ES2188426B1 (es) * 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
KR20050096953A (ko) * 2003-02-05 2005-10-06 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨. 물의 존재에 민감한 하나 이상의 활성제를 함유하는 반전에멀젼 유형 조성물, 및 미용 및 피부과에서의 그의 용도
WO2006051287A1 (en) * 2004-11-10 2006-05-18 Arrow International Limited Composition and method for treatment of alopecia areata

Also Published As

Publication number Publication date
RU2009109356A (ru) 2010-09-27
PT1891960E (pt) 2010-01-04
AU2006347403A1 (en) 2008-02-21
US20080045487A1 (en) 2008-02-21
DE602006009511D1 (de) 2009-11-12
CA2661064A1 (en) 2008-02-21
CN101522198A (zh) 2009-09-02
EP1891960A1 (en) 2008-02-27
MX2009001631A (es) 2009-06-19
RU2432952C2 (ru) 2011-11-10
IL197035A0 (en) 2009-11-18
US7671044B2 (en) 2010-03-02
WO2008020091A1 (es) 2008-02-21
EP1891960B1 (en) 2009-09-30
BRPI0621966A2 (pt) 2011-12-27
ATE444071T1 (de) 2009-10-15
ES2334381T3 (es) 2010-03-09
CN101522198B (zh) 2011-10-05
DK1891960T3 (da) 2010-02-01

Similar Documents

Publication Publication Date Title
MY178634A (en) Topical formulation for a jak inhibitor
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006120682A3 (en) Compositions and methods for treating hyperproliferative epidermal diseases
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
IL178822A (en) Amide @@ - @Phenylamino-Quinzoline-6-YL, medicinal preparations containing them, and their use in the preparation of drugs for the treatment of proliferative disorders
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2008006839A3 (en) Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
IL189270A (en) Repamycins converted to phosphonate and their derivatives, pharmaceutical preparations containing them and their use in the prevention and treatment of bone and joint infections
PT1893237E (pt) Composição farmacêutica compreendendo um elastómero organopolissiloxano e um princípio activo solubilizado
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
EP4241855A3 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2008105088A1 (ja) 脊髄損傷治療薬剤
WO2008025830A3 (en) Pharmaceutical and sunscreen compositions comprising caspase-14
WO2009088673A3 (en) Pharmaceutical composition
EP1741430A4 (en) REMEDY FOR PSYCHO NEUROSIS DISEASES
ES2325291A1 (es) "uso de un extracto de silybum marianum"
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
WO2008020091A8 (es) Formulación farmacéutica para el tratamiento de afecciones
WO2009101497A3 (en) Topical pharmaceutical combination comprising minoxidil and aminexil

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680056111.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06807928

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 197035

Country of ref document: IL

Ref document number: MX/A/2009/001631

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 609/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2661064

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006347403

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009109356

Country of ref document: RU

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06807928

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: PI0621966

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090217